Akebia Therapeutics Inc AKBA Stock Analysis
- Nasdaq
- Stock
- Market closed · opens Monday 9:30 AM ET
$0.40 down $0.02, 5.69% at close Nov 6
Last close · Previous close $0.43
- Market cap
- At the Nov 6 close
- P/E ratio
- n/mLoss over last 12 months
- Diluted EPS
- −$0.11Last 12 months
- Dividend yield
- NoneLast 12 months
Price chart
$0.40down $0.02, 5.69%Fri, Nov 6 session
Use the left and right arrow keys to move along the chart.
Price data
Trading
- Previous close$0.43Nov 5
- Volume11.78MNov 6 session
Shares traded on all US exchanges in the last completed session. Live intraday volume covers IEX only, so it is left out.
- Avg. volume9.35MLast 21 sessions
The average daily shares traded over the last 21 trading sessions, about one calendar month.
- 52-week range: $0.36 to $1.89; now $0.40
The lowest and highest trades over the past 52 weeks, adjusted for splits. The marker shows the latest price.
Member SIPC.Low CommissionsLearn More (opens in a new tab)Sponsored. Affiliate link: I may earn a commission. The inclusion of Interactive Brokers’ (IBKR) name, logo or weblink is present pursuant to an advertising arrangement only. IBKR is not a contributor, reviewer, provider or sponsor of content published on this site, and is not responsible for the accuracy of any products or services discussed.
Performance
Past performance, measured to the Nov 6 close. Total return includes reinvested dividends.Price change only, without dividends. Compared with the S&P 500, using SPY.
AKBA trailed the S&P 500 in all 7 periods.
| Period | AKBA and S&P 500 | vs S&P 500 |
|---|---|---|
| Short term | ||
| 1M | AKBA: down 54.3% S&P 500: down 5.6% | AKBA trailed the S&P 500 by 48.7 percentage points Trailed |
| 3M | AKBA: down 58.0% S&P 500: down 4.1% | AKBA trailed the S&P 500 by 53.9 percentage points Trailed |
| YTD | AKBA: down 75.1% S&P 500: up 8.7% | AKBA trailed the S&P 500 by 83.8 percentage points Trailed |
| 1Y | AKBA: down 80.0% S&P 500: up 10.9% | AKBA trailed the S&P 500 by 90.9 percentage points Trailed |
| Long term | ||
| 3Y | AKBA: down 59.9% S&P 500: up 75.0% −26.2% vs +20.5% a year | AKBA trailed the S&P 500 by 134.9 percentage points Trailed |
| 5Y | AKBA: down 86.3% S&P 500: up 67.8% −32.8% vs +10.9% a year | AKBA trailed the S&P 500 by 154.1 percentage points Trailed |
| 10Y | AKBA: down 94.6% S&P 500: up 313.1% −25.3% vs +15.2% a year | AKBA trailed the S&P 500 by 407.7 percentage points Trailed |
$10,000 invested in AKBA 10 years ago (Nov 4, 2016) would be worth about $545 at the close on , with dividends reinvested. The same amount in the S&P 500 would be worth about $41,313.
AKBA trailed the S&P 500 in all 7 periods.
| Period | AKBA and S&P 500 | vs S&P 500 |
|---|---|---|
| Short term | ||
| 1M | AKBA: down 54.3% S&P 500: down 5.6% | AKBA trailed the S&P 500 by 48.7 percentage points Trailed |
| 3M | AKBA: down 58.0% S&P 500: down 4.3% | AKBA trailed the S&P 500 by 53.7 percentage points Trailed |
| YTD | AKBA: down 75.1% S&P 500: up 7.8% | AKBA trailed the S&P 500 by 82.9 percentage points Trailed |
| 1Y | AKBA: down 80.0% S&P 500: up 9.7% | AKBA trailed the S&P 500 by 89.7 percentage points Trailed |
| Long term | ||
| 3Y | AKBA: down 59.9% S&P 500: up 68.8% −26.2% vs +19.1% a year | AKBA trailed the S&P 500 by 128.7 percentage points Trailed |
| 5Y | AKBA: down 86.3% S&P 500: up 56.9% −32.8% vs +9.4% a year | AKBA trailed the S&P 500 by 143.2 percentage points Trailed |
| 10Y | AKBA: down 94.6% S&P 500: up 252.6% −25.3% vs +13.4% a year | AKBA trailed the S&P 500 by 347.2 percentage points Trailed |
$10,000 invested in AKBA 10 years ago (Nov 4, 2016) would be worth about $545 at the close on , not counting dividends. The same amount in the S&P 500 would be worth about $35,257.
All-time high
$29.17
Closing high on . Now 98.6% below that record.
Split-adjusted daily closes since Mar 20, 2014.
Stock splits
AKBA hasn’t split since its price history begins in 2014.
Valuation
Financials
Reported results, not forecasts. From company filings via Tiingo; the latest report is Q2 FY26, the quarter ended Jun 30, 2026. “Last 12 months” means the four quarters from Jul 1, 2025 to Jun 30, 2026, and balance-sheet figures are as of Jun 30, 2026.
Revenue and net income
Last 12 months, with the change from the 12 months before
- Revenue
- $219.06Mup 7.5%
- Net income
- −$29.67M
- Diluted EPS
- −$0.11
Data table
| Period | Revenue | Net income | Diluted EPS |
|---|---|---|---|
| Q3 FY24 (Sep 30, 2024) | $37.43M | −$20.04M | −$0.10 |
| Q4 FY24 (Dec 31, 2024) | $46.50M | −$22.80M | −$0.11 |
| Q1 FY25 (Mar 31, 2025) | $57.34M | $6.11M | $0.03 |
| Q2 FY25 (Jun 30, 2025) | $62.47M | $247.00K | $0.00 |
| Q3 FY25 (Sep 30, 2025) | $58.77M | $540.00K | $0.00 |
| Q4 FY25 (Dec 31, 2025) | $57.62M | −$12.24M | −$0.05 |
| Q1 FY26 (Mar 31, 2026) | $53.54M | −$9.05M | −$0.03 |
| Q2 FY26 (Jun 30, 2026) | $49.13M | −$8.91M | −$0.03 |
| Period | Revenue | Net income | Diluted EPS |
|---|---|---|---|
| FY21 (Dec 31, 2021) | $211.65M | −$282.02M | −$1.70 |
| FY22 (Dec 31, 2022) | $292.48M | −$94.23M | −$0.52 |
| FY23 (Dec 31, 2023) | $194.62M | −$51.93M | −$0.28 |
| FY24 (Dec 31, 2024) | $160.18M | −$69.41M | −$0.33 |
| FY25 (Dec 31, 2025) | $236.20M | −$5.35M | −$0.02 |
Margins
- Gross 79.6%
- Operating −5.4%
- Net −13.5%
The percentages above the chart cover the last 12 months; the lines show each quarter. What margins tell you
Cash flow
- $40.38MLast 12 months
Cash from operations minus capital spending: the cash left after the business maintains and grows its assets.
FCF = Operating cash flow − Capital spendingFree cash flow - Operating cash flow$41.55MLast 12 months
- Capital spending$1.17MLast 12 months
- 18.4%Last 12 months
Free cash flow as a share of revenue, both over the last 12 months.
Shareholder returns
- $63.71MLast 12 months
Cash spent repurchasing shares, net of shares issued. Buybacks shrink the share count, so each remaining share owns more of the company.
- Dividends paid$0.00Last 12 months
- Total returned$63.71MLast 12 months
158% of free cash flow
Balance sheet
- $155.55MAs of Jun 30, 2026
Cash plus short- and long-term marketable securities on the Jun 30, 2026 balance sheet.
- Total debt$53.96MAs of Jun 30, 2026
- Net cash$101.59MAs of Jun 30, 2026
- 1.43As of Jun 30, 2026
Current assets divided by current liabilities on the Jun 30, 2026 balance sheet. Above 1 means short-term assets cover the bills due within a year.
Current ratio = Current assets ÷ Current liabilitiesCurrent ratio - 2.16As of Jun 30, 2026
Total debt divided by shareholders’ equity on the Jun 30, 2026 balance sheet: a measure of financial leverage.
D/E = Total debt ÷ Shareholders’ equityDebt-to-equity ratio
Financial strength
- 5 of 9Last 12 months
vs the 12 beforeA 0–9 checklist from accounting professor Joseph Piotroski. Each test compares the last 12 months with the 12 months before and scores a point if it passes. 8–9 is strong; 0–2 is weak.
- ✗Net income was positive: not passed
- ✓Operating cash flow was positive: passed
- ✓Return on assets improved: passed
- ✓Operating cash flow exceeded net income: passed
- ✓Long-term debt fell relative to assets: passed
- ✗Current ratio improved: not passed
- ✗Share count didn’t rise: not passed
- ✓Gross margin improved: passed
- ✗Asset turnover (revenue ÷ assets) improved: not passed
- −93.7%Last 12 months
Over the last 12 months, Akebia Therapeutics lost money: its net loss was 93.7% of its shareholders’ equity (averaged over the last four quarter-ends). It describes the past year, not an expected return.
ROE = Net income (last 12 months) ÷ Average equityReturn on equity - −8.2%Last 12 months
Over the last 12 months, Akebia Therapeutics’s net loss was 8.2% of its total assets (averaged over the last four quarter-ends).
ROA = Net income (last 12 months) ÷ Average total assets
About Akebia Therapeutics Inc
Akebia Therapeutics, Inc. is a fully integrated biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease. Akebia was founded in 2007 and is headquartered in Cambridge, Massachusetts.
- Sector
- Healthcare
- Industry
- Biotechnology
- Headquarters
- Massachusetts, USA
- SEC filings
- EDGAR (opens in a new tab)
- Exchange
- Nasdaq
- Asset type
- Common stock
- Price history since
AKBA news
Explore more stocks
Prices are from the last refresh. Open any stock for its live dashboard.
Popular stocks
AKBA stock FAQ
What is AKBA stock’s price today?
Akebia Therapeutics (AKBA) traded at $0.40 at the close on , down $0.02 (5.69%) from the previous close of $0.43. Over the past 52 weeks it has traded between $0.36 and $1.89.
If you invested $1,000 in AKBA 10 years ago, how much would you have now?
With dividends reinvested, $1,000 invested in AKBA on would be worth about $54 at the close on , a total return of −94.6%. The same $1,000 would be worth $137 if invested five years ago and $200 if invested one year ago. Past performance doesn’t predict future returns.
What is AKBA’s P/E ratio?
AKBA’s P/E ratio isn’t meaningful right now because its earnings over the four quarters to are negative (diluted EPS of −$0.11).
How much revenue does Akebia Therapeutics make?
Akebia Therapeutics reported $219.1 million of revenue over the four quarters to , up 7.5% from the twelve months before. In its latest quarter (Q2 FY26, ended ) revenue was $49.1 million, down 21.4% from a year earlier.
Is Akebia Therapeutics profitable?
Not over the four quarters to . Akebia Therapeutics reported a net loss of $29.7 million across those four quarters on $219.1 million of revenue.
What are AKBA’s earnings per share?
AKBA’s diluted earnings per share were −$0.11 over the four quarters to , compared with −$0.18 in the twelve months before. The latest quarter (Q2 FY26) brought −$0.03 per share, against $0.00 a year earlier (how EPS works).
Does AKBA pay a dividend?
Akebia Therapeutics hasn’t paid a dividend in the last twelve months.
What is AKBA’s 52-week high and low?
Over the past 52 weeks AKBA has traded as low as $0.36 and as high as $1.89. At $0.40 at the close on , it is 78.8% below that high and 11.1% above the low.
What is AKBA’s all-time high?
AKBA’s highest closing price was $29.17 on , adjusted for stock splits. At $0.40 at the close on , it is 98.6% below that record.
Has AKBA stock ever split?
No. AKBA hasn’t split since its price history begins in 2014.
How has AKBA stock performed?
Including dividends and measured to the close on , AKBA has returned −75.1% so far this year and −80.0% over the past year, and −86.3% over five years (−32.8% a year). Over the same periods the S&P 500, measured by SPY, returned +8.7%, +10.9% and +67.8%. Past performance doesn’t predict future returns.
What sector and industry is Akebia Therapeutics in?
Akebia Therapeutics is in the Healthcare sector and the Biotechnology industry, and is headquartered in Massachusetts, USA.
What exchange does AKBA trade on?
Akebia Therapeutics trades on the Nasdaq under the ticker symbol AKBA. Its price history on this dashboard begins on .
Member SIPC.Low CommissionsLearn More (opens in a new tab)Sponsored. Affiliate link: I may earn a commission. The inclusion of Interactive Brokers’ (IBKR) name, logo or weblink is present pursuant to an advertising arrangement only. IBKR is not a contributor, reviewer, provider or sponsor of content published on this site, and is not responsible for the accuracy of any products or services discussed.
About this data. Data sourced by Tiingo (opens in a new tab). The live price is Tiingo’s real-time price, based on IEX trades and quotes; intraday charts show IEX trades, and volume figures are consolidated totals for completed sessions. Prices are split-adjusted, and total returns assume dividends are reinvested. Financials come from company filings and can lag new reports. Times are Eastern.
This page is for education, not investment advice. Past performance doesn't predict future returns. Logos provided by Logo.dev (opens in a new tab).
The Interactive Brokers word and logo are trademarks of Interactive Brokers LLC (or its subsidiaries) in the US and/or elsewhere. All rights reserved.